1. Valeant started the year by selling off $2.1 billion in assets.
2. The company has $30.4 billion in lingering debt. Through selling off strategic assets, however, it avoided paying additional interest on a bond.
3. As of Feb. 24, 2017, Valeant shares were trading at $16.24 per share. The company has a 52-week high of $86.50 and a 52-week low of $13.
More articles on gastroenterology/endoscopy:
LifeBond enrolling patients in LifeSeal surgical sealant study: 4 key notes
GI leader to know: Dr. Sam Moussa of Adobe Gastroenterology
5 ways CMS changes are affecting reimbursement for ASCs, anesthesia practices and providers
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
